Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a neutral-cationic peptoid, and/or tautomers, regioisomers, stereoisomers, derivatives, analogues, or pharmaceutically acceptable salts thereof. In some embodiments, the neutral-cationic peptoid comprises η2′;,6′;-Dmt-ηArg-ηPhe-ηLys-NH2, ηPhe-ηArg-ηPhe-ηLys-NH2, or ηArg-η2′;,6′;-Dmt-ηLys-ηPhe-NH2.